Toxicology News and Research

Latest Toxicology News and Research

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announced today the grant of US Patent No. 7,884,318 entitled "Systems, Methods, and Computer-Readable Medium for Determining Composition of Chemical Constituents in a Complex Mixture".

8 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Mothballs may cause brain damage in babies: Experts

Pediatricians have called for a ban on the sale of mothballs containing the chemical naphthalene citing evidence that these can lead to severe blood problems and even brain damage for significant numbers of Australian babies.

7 Feb 2011

Wood smoke may create adverse health effects in humans

With millions of people warding off winter's chill with blazing fireplaces and wood-burning stoves, scientists are raising red flags about the potential health effects of the smoke released from burning wood. Their study, published in the American Chemical Society's journal, Chemical Research in Toxicology, found that the invisible particles inhaled into the lungs from wood smoke may have several adverse health effects.

6 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Receptos, announced today that their highly selective sphingosine-1-phosphate receptor 1 agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.

28 Jan 2011

National Center for Radioecology formed

With the renewed and growing interest in nuclear energy, radioecology experts at the U.S. Department of Energy's Savannah River National Laboratory recognized an immediate need to build the pool of radioecology expertise both here and abroad.

27 Jan 2011

FDA, Simulations Plus sign RCA to develop QSAR toxicity models

Simulations Plus, a leading provider of software for pharmaceutical discovery and development, announced that the U.S. Food and Drug Administration and Simulations Plus have signed a five-year research collaboration agreement to work together to develop Quantitative Structure-Activity Relationship toxicity models for FDA regulatory and research applications.

27 Jan 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

New investigative tool may explore intracellular processes with unprecedented clarity

Nongjian Tao and his colleagues at the Biodesign Institute at Arizona State University have pioneered a new technique capable of peering into single cells and even intracellular processes with unprecedented clarity.

25 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

Mercury, the main ingredient in "silver" or amalgam fillings, will be the subject of a United Nations conference to be held in Chiba, Japan on January 24-28. Members of various non-governmental organizations, as well as dentists and scientists from groups such as the International Academy of Oral Medicine and Toxicology, will be attending and urging a ban on products containing mercury, including dental amalgam.

21 Jan 2011

New study provides insight into developing therapeutics for airway disease

Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

19 Jan 2011

Smoking harms DNA within minutes: Study

According to the latest research in the US, smoking tobacco damages the body in minutes rather than years. The study was published in the Chemical Research in Toxicology revealed that the chemicals which cause cancer form rapidly after smoking.

16 Jan 2011

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2011 ended November 30, 2010 (1QFY11).

14 Jan 2011

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced commencement of operations on the initial phase of production at the Company's Fengxian facility. This new multi-purpose pharmaceutical development and cGMP manufacturing facility is located in Fengxian in the suburbs of Shanghai, China.

14 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

Toxicology News and Research

Latest Toxicology News and Research

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Mothballs may cause brain damage in babies: Experts

Wood smoke may create adverse health effects in humans

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

National Center for Radioecology formed

FDA, Simulations Plus sign RCA to develop QSAR toxicity models

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

New investigative tool may explore intracellular processes with unprecedented clarity

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

NGOs, IAOMT urge to ban mercury-containing products, including dental amalgam

New study provides insight into developing therapeutics for airway disease

Smoking harms DNA within minutes: Study

Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M

ShangPharma opens new multi-purpose pharma development and cGMP manufacturing facility in Fengxian

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Celator, Cephalon extend cancer research agreement

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Toxicology News and Research

Latest Toxicology News and Research

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in